

## Vaccine Associated Paralytic Poliomyelitis Unmasking Common Variable Immunodeficiency

**SUNIL GOMBER, VANNY ARORA AND POOJA DEWAN**

*From Department of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, Delhi 110095, India.*

*Correspondence to: Dr Sunil Gomber, Director-Professor, Department of Pediatrics, Guru Teg Bahadur Hospital, Dilshad Garden, Delhi 110 095, India. sunilgomber@hotmail.com  
Received: May 10, 2016;  
Initial review: August 11, 2016;  
Accepted: January 12, 2017.*

**Background:** Oral polio vaccine can rarely lead to Vaccine-associated paralytic poliomyelitis (VAPP). **Case characteristics:** A 2-year-old child with asymmetric paralysis of lower limbs following first booster of oral polio vaccine; type 2 Vaccine-derived poliovirus (VDPV) isolated. Subsequently, the child was diagnosed to have common variable immunodeficiency. **Outcome:** Paralysis gradually improved on follow-up; monthly intravenous immunoglobulin therapy started for primary immunodeficiency. **Message:** We need to evaluate children with VAPP for underlying immunodeficiency.

**Keywords:** Immunization, Oral polio vaccine, Vaccine-derived poliovirus.

Immunity to polioviruses and other human enteroviruses is mediated by neutralizing antibody [1]. Prolonged intestinal replication of the poliovirus from oral polio vaccine (OPV) in immunodeficient patients, increases the chances of reversion to neurovirulence and transmissibility characteristics typical of wild poliovirus strains. In immunocompetent persons, the duration of intestinal infection by poliovirus is typically limited to 4-8 weeks [2]. In contrast, in immunodeficient persons, particularly those with B-cell deficiency which is associated with hypogammaglobulinemia, poliovirus excretion can persist for as long as 3.5 years [3]. In India, till date, 43 cases of vaccine-derived polioviruses (VDPV) have been reported [4]. We herein describe occurrence of VAPP in a two-year-old child three months following the first booster of OPV.

### CASE REPORT

A two-year-old girl presented with sudden-onset of weakness of left lower limb of one month duration. The weakness was preceded by fever and cough for one day. Weakness progressed over the next month to involve right lower limb and weakness of left half of face. The parents gave a history of administration of first booster of OPV one- and-a-half month prior to onset of weakness in the child. There was no significant past illness requiring any hospitalization or prolonged antibiotics intake in child except recurrent fever, with cough and coryza over the previous four months. There was no significant family history.

Examination revealed stable vitals and mild pallor.

Child was conscious and well oriented. The child was not able to close left eye and nasolabial fold of left side was less prominent. Muscles of lower limbs were flabby to touch (right > left) with wasting of right lower limb, with decreased power in both lower limbs (1/5 in right lower limb and 2/5 in left lower limb) and diminished reflexes in right lower limb. Rest of examination was unremarkable.

Routine hematological and biochemical investigations, including muscle enzymes, were within normal limits. Asymmetric motor sensory predominantly axonal polyneuropathy was found on nerve conduction velocity assessment of both lower limbs, and MRI dorsolumbar spine was normal. The child was investigated as a case of Acute flaccid paralysis.

Stool sample collected on 3<sup>rd</sup> and 5<sup>th</sup> day of onset of paralysis showed VDPV type 2 virus with 24 nucleotide changes. Immunological workup suggested pan-hypogammaglobulinemia with IgG <0.187 g/L (3.7-15.8), IgA <0.068 g/L (0.3-1.3), and IgM 0.195 g/L (0.5-2.2). Markedly reduced isohaemagglutinin titres suggested of an impaired antibody response to antigen with Anti-A titre of IgM : 1:1 ; IgG : 1:2 and Anti-B titre of IgM: 1:2; IgG: 1:4 and normal number of B and T lymphocytes with values of CD 19+ B- cells 18.94 % (14-33%), naïve B-cell count 94.8% (62-69%), memory B-cell 4.61% (8-22%), CD3+ T cells 74.5% (56-75%), helper T-cell count 37.15% (33-55%), cytotoxic T-cell 36.4% (14-26%) NK cell count 0.64% (4-17%). The findings of presence of normal number of B and T cells with panhypoglobulinemia were consistent with diagnosis of Common variable immunodeficiency.

The child's weakness did not progress and she was started on intravenous immunoglobulin (IVIg)(400 mg/kg/day for 5 days). Her weakness improved over the next month. She was continued on monthly IVIg. Eight months after diagnosis, the excretion of polio virus continues to persist.

## DISCUSSION

Polio virus isolates are described as VDPV or wild type poliovirus based on the percent nucleotide sequence homology between its capsid protein VP1 and that of the corresponding OPV vaccine serotype. VDPVs are further subdivided as "i-VDPV" that arise during persistence infection of immunodeficient individuals and "c-VDPV" or "circulating VDPV" that evolve during continuous transmission of vaccine virus among unvaccinated individuals in populations with low vaccination coverage and sufficient numbers of unimmunized infants accumulate [5] and 'ambiguous VDPVs (aVDPVs)' which are either clinical isolates from persons with no known immunodeficiency, or sewage isolates of unknown source [6]. Occurrence of VAPP following OPV administration is rare, the incidence being rarer after subsequent doses compared to the first dose of oral vaccine. Paralytic disease in immunodeficient patients following their vaccination with OPV has been recognized for a long time [7], but only during the past decade has the phenomenon received the deserved scrutiny.

Aforementioned patient developed acute paralysis three months following booster dose of OPV. As the patient had underlying immunodeficiency, the vaccine virus likely reverted back to neurovirulence and resulted in development of paralysis. Kew, *et al.* [8] described a case of VDPP in a patient of common variable immunodeficiency, but this patient was a known case of CVID before paralysis onset, which occurred 6.9 years after vaccination and at least 2 years after diagnosis of CVID. This is unlike our case, where diagnosis of immunodeficiency was made after the isolation of vaccine polio virus. Type 2 vaccine virus is the predominant cause of VDPV worldwide, as well as in India [1].

Several strategies for eliminating poliovirus persistence in immunodeficient patients have been tried with equivocal results. Review of literature revealed that most persons with hypogammaglobulinemia who were fed OPV while receiving immunoglobulin replacement therapy cleared the infection within a few weeks [9]. In the present case, excretion of virus is persisting even months after monthly pulses of immunoglobulin.

This case further endorses the recommendation of the Government of India and WHO to switch from oral vaccine to inactivated vaccine to minimize the risk of paralysis, especially in immunocompromised children as screening for primary immunodeficiency is not possible prior to first dose of OPV. A step has already been taken in this direction with the introduction of one dose of IPV at 14 weeks of age in the National immunization program [10].

*Acknowledgements:* Prof Surjit Singh from PGI for carrying over detailed immunoprofile of the child. Dr Preeti Nigam, SMO NPSP for co-ordinating initial viral work up at NCDC, Civil Lines, Delhi. The advanced virology workup was done at ERC, Mumbai.

*Contributors:* SG: Analyzed the case, designed the work-up and helped in drafting the manuscript; VA: worked up the case and drafted the manuscript; PD: Helped to diagnose the disease and contributed in drafting the manuscript.

*Funding:* None; *Competing interest:* None stated.

## REFERENCES

1. McKinney RE, Jr, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. *Rev Infect Dis.* 1987;9:334-56.
2. Alexander JP, Gary HE, Pallansch MA. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. *J Infect Dis.* 1997;175S1:176-82.
3. Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. *J Infect Dis.* 1997;175S1:S286-92.
4. World Health Organization. India polio status, as on 1 August 2014. Available from: [www.searo.who.int/india/topics/poliomyelitis/polio-frequently-asked-statistics\\_04aug%202014.pdf?ua=1](http://www.searo.who.int/india/topics/poliomyelitis/polio-frequently-asked-statistics_04aug%202014.pdf?ua=1). Accessed February 12, 2017
5. Key OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, Nathanson N, *et al.* Circulating vaccine-derived polioviruses: current state of knowledge. *Bull World Health Organ.* 2004;82:16-23.
6. Centre for Disease Control and prevention. Update on vaccine-derived polioviruses. *Mortal Wkly Rep.* 2006;55:1093-7.
7. Wyatt V. Risk of live poliovirus in immunodeficient children. *J Pediatr.* 1975;87:152-3.
8. Kew OM, Sutter RW, Nottay BK. Prolonged replication of a type 1 vaccine derived poliovirus in an immunodeficient patient. *J Clin Microbiol.* 1998:2893-9.
9. Martin J, Dunn G, Hull R, Paterl V, Minor P. Evolution of the strain of type 3 poliovirus in an immunodeficient patient during the entire.637-day period of virus excretion. *J Virol.* 2000;74:3001-10.
10. Indian Academy of Pediatrics (IAP) Advisory Committee on Vaccines and Immunization Practices (ACVIP); Jog P, Kamath SS, *et al.* Introduction of inactivated poliovirus vaccine in National Immunization program and polio end game strategy. *Indian Pediatr.* 2016;53(Suppl.1):566-9.